The questions everyone has.
Answered straight.

Peptides are short chains of amino acids — the same building blocks that make up proteins. Your body produces hundreds of them naturally. They act as chemical messengers, telling your cells to do specific things: repair tissue, release hormones, regulate inflammation, manage metabolism. Researchers study synthetic versions of these natural peptides to understand how those processes work and what happens when you enhance them. Think of them as very precise biological signals — not drugs in the traditional sense, but molecules that work with systems your body already uses.

A few things hit at once. GLP-1 compounds like semaglutide — the active ingredient in Ozempic — became headline news for their metabolic research findings. At the same time, the fitness and biohacking communities discovered recovery compounds like BPC-157 and TB-500 through published preclinical research. The volume of peer-reviewed studies has grown dramatically, the findings have been compelling, and social media brought it all mainstream. The interest is real — and so is the science behind it.

It means the compound has not been approved by the FDA for human therapeutic use. It's intended for laboratory research, in-vitro studies, or animal research — not for personal use as a treatment or supplement. It is not illegal to purchase or possess. It is not a judgment about the compound's quality or the science behind it. The RUO designation reflects regulatory status — the compound hasn't completed the FDA's formal drug approval process, which costs over $1 billion and takes 10-15 years. Most research peptides haven't gone through that process, not because they've failed, but because no pharmaceutical company has funded the full approval pathway for them.

No — and the distinction matters. Anabolic steroids are synthetic derivatives of testosterone that directly affect hormone levels in ways that can significantly disrupt your endocrine system. SARMs are selective androgen receptor modulators that target muscle and bone tissue specifically. Research peptides are a separate category — they typically work with your body's existing signaling systems rather than flooding receptors with hormones. GH axis peptides like CJC-1295 and Ipamorelin, for example, prompt your own pituitary to release growth hormone naturally rather than introducing exogenous HGH. They are researched differently, regulated differently, and work through completely different mechanisms.

Amino acids are the individual building blocks of proteins and peptides. Think of them like LEGO bricks — each one has a specific shape and function, and connecting them in different sequences creates different molecules that do different things. Your body uses 20 different amino acids to build everything from muscle tissue to enzymes to hormones. A peptide is simply a short chain of amino acids — BPC-157 is a chain of 15, GHK-Cu is just 3. The sequence and length determine what the peptide does in the body.

Semaglutide is the active molecule. Ozempic and Wegovy are brand-name pharmaceutical products that contain semaglutide, manufactured by Novo Nordisk, approved by the FDA for specific medical uses, and dispensed through a prescription. Research-grade semaglutide is the same molecule — synthesized for research use, not pharmaceutical use. It has not gone through the same FDA approval process, is not the same product as Ozempic, and cannot be legally used as a substitute for an FDA-approved medication. The distinction is important and every legitimate supplier makes it clearly.

BPC-157 stands for Body Protection Compound — a 15-amino acid sequence derived from a protein found naturally in gastric juice. It's one of the most studied recovery compounds in current preclinical literature with hundreds of published studies. Research has examined its effects on tendon and ligament repair, gut lining integrity, tissue healing acceleration, and anti-inflammatory pathways. Animal studies have shown accelerated tendon-to-bone healing and improved gut barrier function. No large human clinical trials have been completed — which is why it remains a research-use compound. It is available from ReViaLife with a third-party CoA for every batch. View verified source →

BPC-157 works locally — it targets the specific site of injury or inflammation, signaling repair at the tissue level. TB-500 works systemically — it's a fragment of Thymosin Beta-4 that mobilizes cells throughout the body to support recovery. They're frequently studied together precisely because they cover different ground: BPC-157 for localized repair signaling, TB-500 for body-wide cellular migration toward damaged tissue. Together they address both local and systemic recovery pathways — which is why the combination is called the "recovery stack" and is one of the most researched pairings in peptide literature.

Semaglutide targets one receptor — GLP-1. Tirzepatide targets two simultaneously — GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide). GLP-1 primarily affects appetite signaling and blood sugar. GIP affects fat storage and metabolism through different pathways. Research has shown that hitting both receptors simultaneously produces a different — and in many studies, more pronounced — metabolic profile than GLP-1 alone. Tirzepatide is the compound in Mounjaro and Zepbound. Research-grade tirzepatide is the same molecule studied outside the pharmaceutical setting — for research use only.

The most studied metabolic compounds are semaglutide (GLP-1 agonist) and tirzepatide (GLP-1 + GIP dual agonist) for their effects on appetite regulation and metabolic function. For body composition specifically, CJC-1295 and Ipamorelin are widely studied for their interaction with the growth hormone axis and effects on lean mass in animal models. These are distinct mechanisms — GLP-1 compounds primarily affect appetite and metabolic function; GH axis compounds primarily affect body composition through growth hormone release patterns. All are research-use compounds only.

GHK-Cu is a naturally occurring copper complex — a tripeptide that your body produces and that declines significantly with age. Published research has examined its role in stimulating collagen and elastin synthesis, accelerating wound healing, and activating genes associated with tissue repair. It's one of the most studied compounds in longevity and cosmetic research. Some high-end skincare products include it in cosmetic formulations — though research-grade concentrations and applications differ significantly from over-the-counter cosmetic use. Research-grade GHK-Cu is available from ReViaLife for laboratory research use. View verified source →

Five questions that disqualify most suppliers instantly:

1. Do you provide a third-party CoA for this specific batch? Not a generic one. Batch-specific, from an independent lab.

2. Who is the testing laboratory? Can you verify them independently? A legitimate supplier names their lab. You should be able to Google it.

3. Is your manufacturing facility cGMP certified? Which facility? Is it FDA-registered?

4. Do you test for endotoxins? A compound can be 99% pure and still be endotoxin-contaminated. Most low-quality suppliers skip this test.

5. Where are your active ingredients sourced? China and India are not disqualifying on their own, but a supplier that can't answer this question clearly is a red flag.

ReViaLife answers all five directly. See their verification standards →

A CoA is a third-party lab report confirming what's actually in the compound you're buying. A legitimate CoA includes: the specific compound name and batch number, HPLC purity percentage (should be above 98% — ReViaLife's standard is 99%+), LC-MS mass spectrometry confirming compound identity, endotoxin testing results in EU/mg, the name of the independent laboratory, and the date of analysis.

Red flags: testing done by the supplier's own lab, no batch number, missing endotoxin testing, a purity range instead of a specific number, a lab name that can't be independently verified, or a single CoA used for multiple batches. Read the full CoA guide →

cGMP stands for Current Good Manufacturing Practice — the FDA's rulebook for pharmaceutical-grade manufacturing. It covers facility cleanliness, ingredient testing, batch tracking, contamination prevention, and record keeping. A cGMP-certified facility has been inspected and certified to follow these standards. For research compounds it means the product was made under pharmaceutical-grade conditions — not in an unregistered overseas operation. ReViaLife's manufacturer is a Florida-based 503(b) outsourcing facility — FDA-registered, cGMP and ISO certified, and held to physician-grade manufacturing standards. That's the highest bar in this category.

Section 503(b) of the Federal Food, Drug, and Cosmetic Act created a category of FDA-regulated "outsourcing facilities" — essentially compounding operations that function at pharmaceutical scale with full regulatory oversight. A 503(b) facility is FDA-registered, follows cGMP standards, undergoes regular FDA inspections, and can produce compounds without patient-specific prescriptions. It's the highest level of manufacturing accountability available for compounded and research compounds in the US. ReViaLife sources from a 503(b) facility based in Florida — the same category of facility used by hospital systems and licensed medical practices.

US manufacturing isn't just geography — it's accountability. US cGMP-certified facilities are subject to FDA inspection and enforcement. Overseas facilities, particularly in China and India, operate under different regulatory frameworks with limited US oversight. Independent testing of overseas-sourced peptides has found substantially lower purity rates — 70-85% is common versus 99%+ from US cGMP facilities. The remaining percentage isn't just missing active compound — it's unknown material. ReViaLife's active ingredients are sourced from Germany and Ukraine — not China or India — and manufactured in a Florida 503(b) facility. That supply chain is documented and verifiable.

Endotoxins are toxic substances released from bacterial cell walls — they persist even after bacteria are killed. A compound can test at 99% chemical purity and still be dangerously contaminated with endotoxins because standard HPLC purity testing doesn't detect them. Endotoxin testing requires a separate LAL (Limulus Amebocyte Lysate) test. Most low-quality suppliers skip this. A CoA that doesn't include endotoxin results is incomplete — period. ReViaLife tests every batch for endotoxins and publishes the results on every CoA. It's one of the things that separates pharmaceutical-grade manufacturing from everything else in this market.

In the United States, research peptides sold under a Research Use Only designation are not controlled substances and are generally legal to purchase and possess for research purposes. They exist in a regulated but complex space — not FDA-approved pharmaceuticals, but also not illegal drugs. The regulatory landscape shifts — specific compounds have been reclassified at various points — which is why staying informed matters. ReViaWell tracks regulatory developments and updates this resource accordingly. Nothing on this site constitutes legal advice. For jurisdiction-specific questions, consult an attorney familiar with research compound law.

In 2022, the FDA added BPC-157 to a list of compounds that may not be compounded by 503A and 503B facilities for use in humans — citing insufficient evidence of safety and effectiveness for therapeutic use. This affected compounding pharmacies producing BPC-157 for clinical administration. It did not make BPC-157 illegal to sell or possess as a research compound under RUO designation. The compound remains available from research suppliers. The regulatory status continues to evolve — Pentadeca Arginate (PDA) emerged partly as a structurally similar alternative in the wake of increased scrutiny on BPC-157.

The gray market is the space between clearly legal and clearly illegal. Research compounds aren't black market drugs — they're sold under legally recognized RUO designations that place them outside FDA's pharmaceutical approval framework. The gray market exists because FDA drug approval takes 10-15 years and over $1 billion per compound. Most peptides haven't gone through that process — not because they've failed, but because no company has funded the full pathway for them. The risk in the gray market isn't the compounds themselves — it's the quality of suppliers operating within it. Verified sourcing standards — CoA verification, cGMP manufacturing, endotoxin testing — are exactly what makes operating in the gray market safe. Without them, it isn't.

Robert F. Kennedy Jr. served as Secretary of Health and Human Services in 2025. He has been publicly critical of FDA restrictions on research compounds and broadly supportive of what he terms "health freedom" — the position that individuals should have greater access to compounds being studied in research settings. His elevation to HHS Secretary brought significant attention to the regulatory environment around peptides and has influenced policy discussions that could meaningfully affect the research compound landscape. ReViaWell presents this context factually. We take no political position. What doesn't change regardless of political climate is the importance of sourcing verified, tested compounds from accountable suppliers. Full RFK context in the library →

ReViaWell is the education and verification resource — what you're reading right now. Plain-English compound information, sourcing standards, research guides, and the tools to make informed decisions. Free. No products sold here.

ReViaLife is the research compound supplier — built to the same standards documented in this library. Third-party CoA on every batch, cGMP and ISO certified US manufacturing from a Florida 503(b) facility, HPLC + LC-MS purity verification, endotoxin and sterility testing, domestic cold-chain fulfillment. Same company, different purpose. ReViaWell educates. ReViaLife delivers.

Because the accountability is documented and verifiable — not claimed. Every batch has a published third-party CoA from an independent laboratory. The manufacturing facility is a Florida-based FDA-registered 503(b) outsourcing facility — the same category used by hospital systems and licensed medical practices. Active ingredients are sourced from Germany and Ukraine, not China or India. The 5-stage testing protocol covers HPLC purity, LC-MS identity, sterility, endotoxin, and heavy metals. ReViaLife is also LC-MS tested post-reconstitution — after the compound is dissolved into solution, exactly as it enters use. No other peptide supplier in this market does that. See the full verification standard →

Yes — ReViaWell and ReViaLife are operated by the same company, ReVia LLC. We disclose this transparently because we believe the standard we hold our supply chain to speaks for itself. The education here is genuine — built because the resource didn't exist and the market needed it. The referral relationship between the two sites exists because ReViaLife is built to the standard we document here, not the other way around. We'd rather be honest about the relationship than pretend it doesn't exist.

Use the contact form at reviawell.com/contact — we respond to every question. For compound-specific research questions, the full library at reviawell.com/libraryfull covers 85+ compounds and dozens of terms. For order-related questions about ReViaLife, contact them directly at contact@revialife.com or (305) 290-1462.